コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ary mitral regurgitation (MR) is a prevalent valvular lesion.
2 ed effectively by correcting the responsible valvular lesion.
3 be associated with the development of these valvular lesions.
4 ese enzymes, and (4) development of TAAs and valvular lesions.
5 dex, and renal function were associated with valvular lesions.
6 s known about the long-term outcomes of mild valvular lesions.
7 overload that may result from hypertension, valvular lesions, acute, or chronic ischemic injuries.
8 therapy was halted in 1997 after reports of valvular lesions affecting almost one third of patients
9 ease remains unclear, although regression of valvular lesions after the end of treatment has been rep
11 h malignancies, autoimmune diseases, cardiac valvular lesions, and in patients on mechanical circulat
12 aortic size in control patients with matched valvular lesions (aortic regurgitation, aortic stenosis,
14 urgical treatment of stenotic or regurgitant valvular lesions can alter the natural history of the di
15 promise to offer a novel approach to correct valvular lesions, especially in this high-risk surgical
16 f this study indicate an association between valvular lesions, even at mild stage, and a long-term ri
19 ssociation between apoE alleles and calcific valvular lesions in 802 patients undergoing transthoraci
20 safe and durable surgical correction of the valvular lesions in up to 31% of these high-risk cases.
23 thoracic echocardiography (TTE) identified a valvular lesion of acute Q fever endocarditis without un
25 tity, acute Q fever endocarditis, defined as valvular lesion potentially caused by C. burnetii: veget
27 idate the mechanism of "fen-phen"-associated valvular lesions, we examined the interaction of fenflur
29 ansthoracic echocardiography for significant valvular lesions within a mean of 97 days from the manuf